It was a great day for Alzheimer’s drug developers, regardless of the type of therapies in their pipelines, on 7 June when the US Food and Drug Administration granted accelerated approval for Biogen, Inc./Eisai Co., Ltd.’s amyloid-clearing antibody Aduhelm (aducanumab). The closely watched decision was hailed by patient advocates, research groups and investors as an advance for the Alzheimer’s field that will boost investment in drugs for the disease.
Companies with candidates in late-stage development, such as Eli Lilly and Company and Cortexyme, Inc., saw their stock...
